Abstract. The activation of Janus kinase 1 (JAK1) has been reported to occur in non-small cell lung cancer (NSCLC), activating the JAK/signal transducers and activators of transcription cascade. However, the association between JAK1 activation and the prognostic value in NSCLC remains unclear. The present study initially investigated the association between expression of the activated form of JAK1 (p-JAK1) and prognosis in patients with NSCLC.
Introduction
Lung cancer is one of the leading causes of cancer-associated mortality, accounting for 27% (including 26% for females, and 28% for males), and non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer-associated mortalities (1, 2) . Despite advances in the understanding of the molecular mechanisms of lung cancer and the development of novel chemotherapeutic agents, the 5-year survival rates for lung and bronchus cancer remained <18% from 2004 to 2010 (2) . A number of studies have focused on progressing the understanding of oncogenic kinase signaling pathways, which has provided targets for developing effective therapeutic strategies in order to improve clinical outcomes (3) .
One of the potential candidates for therapy is the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. JAK/STAT is one of the pleiotropic cascades that may transduce a multitude of signals for development and homeostasis in animals, from humans to flies (4) . JAK family members have been reported to be dysregulated in malignant tumors, including in colorectal, prostate and myeloproliferative cancer (5) (6) (7) (8) . The mammalian JAK family includes four members: JAK1, JAK2, JAK3 and Tyk2. All JAKs exhibit broad patterns of expression with the exception of JAK3, which is restricted to leukocytes (9) . JAK1 binds to various cytokines non-covalently to mediate cell proliferation and differentiation (10) . JAK1 knockout mice die perinatally (9) . JAK1 mutation has been reported in hepatocellular carcinoma, acute lymphoblastic leukemia, lung and gastric cancer (10, 11) . Phosphorylated (p)-JAK1, the active form of JAK1, mediates the phosphorylation of receptors and the major substrates for JAK family members, STATs (4). For example, p-JAK1 expression was detected in primary esophageal squamous cell carcinoma and not in normal esophageal squamous cells. p-JAK1 expression was associated with a reduced overall survival time (12) . Additionally, a previous study by the present authors demonstrated that JAK1 expression was significantly increased in NSCLC clinical samples compared with normal samples (P>0.001), while p-JAK1 (Tyk 1022) showed trends of positive expression, though these did not reach statistical significance (P= 0.055), potentially owing to a small sample size (13) . This indicated that JAK1 activation was abnormal in NSCLC.
Lung adenocarcinoma (ADCC) is the most common histological subtype of NSCLC. Patients with ADCC and a high epidermal growth factor receptor (EGFR) copy number can be treated with EGFR-tyrosine kinase inhibitors (14, 15) . EGFR gene amplification has also been reported to be associated with prognosis of lung cancer, though there is some controversy in this regard (16, 17) . However, the combination of EGFR gene amplification and JAK1 activation for predicting cancer prognosis has not been extensively studied. This has incited the present study, which will investigate associations between JAK1 activation, EGFR gene amplification and survival status in patients with NSCLC.
Materials and methods
Tissue collection. The study cohort consisted of 142 patients (40 female and 102 male) with a median age of 63 years (range, 20-84 years). A total of 142 paraffin-embedded resected primary NSCLC samples were analyzed from the archives of the Pathology Department at Sichuan Provincial People's Hospital (Chengdu, China) from December 2004 to February 2007, including 74 cases of ADCC and 68 cases of squamous cell carcinoma (SqCC) A total of 142 adjacent normal pulmonary tissue specimens were also resected in the same tissue blocks. Staging was performed according to the International Union Against Cancer's tumor-node-metastasis system (18) . Differentiation and histological type were scored according to the World Health Organization classification for NSCLC (19) . None of the patients had received neoadjuvant therapy prior to surgical resection. Following the surgery, the patients underwent standard therapy procedure, according to the National Comprehensive Cancer Network Clinical Practice Guideline for Oncology, NSCLC, 2004 (20) . Informed consent was obtained from all individuals included in the present study. Institutional review board approval for the study was obtained from Sichuan Provincial People's Hospital.
Immunohistochemical staining (IHC) . IHC staining was performed as previously described (3) . Briefly, the 4-µm sections underwent deparaffinization, hydration and endogenous peroxide blocking. Antigen retrieval was performed by heating at 95˚C for 30 min in Tris/ethylenediaminetetraacetic acid retrieval solution. The sections were blocked with 3% bovine serum albumin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and incubated with primary p-JAK1 antibody (cat. no. 11149, 1:100 dilution; Signalway Antibody LLC., College Park, MY, ML, USA) overnight at 4˚C. The membranes were subsequently incubated with enough secondary peroxidase-labeled polymer-conjugated goat anti-rabbit antibody to cover the specimen (cat. no. K4007; undiluted; EnVsion; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), according to the manufacturer's protocol, for 30 min at room temperature. For staining, 3,3-daiminobenzidine chromogen was applied. Finally, the sections were counterstained with hematoxylin for 3 min at room temperature, fixed and mounted.
Scoring for immunohistochemical staining. Scoring for immunochemical staining was evaluated as previously described (3) by two independent pathologists. Briefly, the expression of p-JAK1 was assessed semi-quantitatively on the basis of criteria that accounted for the fraction and intensity of immunostaining of the tumor cells. The fraction score was defined as: 0 (0%), 1 (<20%), 2 (20-50%) and 3 (>50%). The intensity of p-JAK1 staining was scored as 0 (no appreciable staining), 1 (barely detectable staining), 2 (readily identifiable brown staining) and 3 (dark brown staining). A total score was calculated by multiplying the fraction and the intensity score. A tumor sample was considered positive if the score was ≥4, and negative otherwise.
Determination of EGFR gene amplification by fluorescence in-situ hybridization (FISH). EGFR FISH analysis was performed with the dual-color EGFR SpectrumOrange/CEP7
SpectrumGreen probe and paraffin pretreatment reagent kit (both from Vysis; cat. nos. 05J48-001 and 32-801210, respectively; Abbott Laboratories, Chicago, IL, USA) as previously described (21) . Briefly, the paraffin sections were deparaffinized, dehydrated and digested with protease K. The slides were denatured by heating to 75˚C for 5 min and dehydrated in ethanol. The probes were denatured for 5 min at 75˚C prior to hybridization. Each slide was hybridized at 37˚C overnight and washed in 2X saline-sodium citrate buffer/0.3% NP40 at 72˚C for 2 min. The nuclei were counterstained with DAPI/antifade 1 (Vysis; Abbott Laboratories, Chicago, IL, USA). A minimum of 100 non-overlapping tumor cell nuclei were scored in each case, according to the University of Colorado Cancer Center criteria (22) . The BX-51/Genus FISH Imaging system (DP71/70/DP30BW software, DP-BSW Ver.03.02) was used for imaging (Olympus, Tokyo, Japan). 
Results

JAK1 expression in non-small cell lung cancer tissues.
Representative IHC staining images of p-JAK1 expression in NSCLC and adjacent normal lung tissues are displayed in Fig. 1 . Positive p-JAK1 expression was observed in the cytoplasm and nucleus, as indicated by arrows. In the NSCLC tissues, 56/142 cases (39.4%) exhibited positive p-JAK1 expression, whereas 11/142 cases (7.7%) were positive in the adjacent normal tissues (Table I) . The difference was highly significant (P<0.001). Table II , follow-up information was available for all patients. Survival time differed significantly by age (>60 vs. ≤60), lymph node invasion (N0/1 vs. N2/3) and stage (I/II vs. III/IV; P=0.005, P<0.001 and P=0.001, respectively). Gender, tumor size and histological type were not significantly associated with survival time.
Association between clinical characteristics and prognosis in patients with NSCLC. As listed in
Association between clinical characteristics and p-JAK1 expression. Pearson's χ 2 or Fisher's exact test were performed to assess the significance of associations between clinical characteristics and p-JAK1 expression. As shown in Table III , p-JAK1 expression was associated with histological type, as 29.7% of ADCC samples and 50.0% of SqCC samples were p-JAK1 + (P=0.014). p-JAK1 expression status was also associated with tumor size and stage (P=0.021 and P=0.009, respectively). Other clinical characteristics, including age, gender, lymph node invasion and distant metastasis, were not associated with p-JAK1 expression status (P>0.05).
Survival status and p-JAK1 expression.
Positive p-JAK1 expression was associated with a poor prognosis in NSCLC (P=0.039; Fig. 2A-C) . However when divided by histological type, the difference was only statistically significant in ADCC samples (P=0.007) and not in SqCC (P=0.612). Subjects with p-JAK1 expression demonstrated reduced survival time in early stage NSCLC, including patients with tumor size <3 cm, N0/1 and stage I/II (P=0.016, P=0.034 and P=0.048, respectively; Fig. 3A-F) . The difference in survival time in patients with late stage disease, including tumor size ≥3 cm, N2/3 or stage III/IV was not significant.
Survival status and p-JAK1 and EGFR expression in ADCC.
To investigate whether associations between JAK1 activation, EGFR gene amplification and prognosis in patients with ADCC were significant, EGFR status was examined with FISH analysis, and univariate survival analyses were performed for the 74 ADCC subjects (Table V) . EGFR gene amplification was determined by FISH (Fig. 4) Fig. 5 ). The results indicated that the EGFR amplification and p-JAK1 + combination may be a novel target to inform the selection of individual therapy strategies and for predicting the effect of therapy in ADCC.
Discussion
Phosphorylation of JAK1 is important for the activation of JAK/STAT pathways and their downstream cascades (10) . In the present study, it was identified that the activation of JAK1 was associated with a poorer prognosis in NSCLC (P=0.039), particularly in ADCC (P= 0.007). p-JAK1 was identified as an independent predictor for poor prognosis (P=0.022). Overall survival time for patients with p-JAK1 + and EGFR gene duplication was significantly reduced compared with patients with one or neither trait (P=0.001).
A previous study by the present authors and studies by others have indicated that inhibition of JAK signaling exhibits anticancer and anti-angiogenetic effects in human cancer lines and xenograft tumors, including lung cancer (13, (23) (24) (25) . These results support the hypothesis that JAK1 activation is important for tumorigenesis in NSCLC. In the present study, when subdivided by histotype, differences in prognosis were identified as statistically significant. Positive p-JAK1 was an independent predictor for decreased survival times only for patients with ADCC, not SqCC. This finding suggests a specific role for JAK1 in lung ADCC. In several lung ADCC cell lines, JAK family inhibitor AZD1480 has demonstrated to be able to potently block STAT3 signaling and oncogenesis (24) , which supports the results of the present study to some extent. However, the research on the effect of p-JAK1 expression on prognosis in lung SqCC has been limited. You et al (12) reported that JAK/STAT pathway activations were associated with shorter survival time in esophageal SqCC cases. As only 68 cases of SqCC patients were recruited to the present study, further evaluation should be performed using a larger amount of cases.
In the present study, it was further identified that tumor size <3 cm, N0/1 and stage I/II patients with positive p-JAK1 expression had shorter survival time (all P<0.05), whereas the difference was not significant for patients in advanced stages (Fig. 3 ). This finding indicated that the activation of JAK1 may be an early event in the tumorigenesis of NSCLC. Therefore, p-JAK1 could be a target for early diagnosis and prognosis prediction.
In the present study, patients with p-JAK1 + and EGFR duplication exhibited the poorest prognosis while patients with p-JAK1 -and no EGFR duplication exhibited the most favorable prognosis (median survival time, 16 vs. 61.5 months). Although contradictory results were previously reported (14, 15) , EGFR FISH status alone was not associated with the patient survival times (data not shown). To date, few studies have focused on the interaction between EGFR and JAKs at the cellular and molecular level. However, it has been identified that crosstalk between the JAK/STAT and EGFR pathways mediates adenomatous polyposis coil 1-driven intestinal stem cell hyperplasia in drosophila (26) . Furthermore, prolactin, a JAK2-coupled cytokine receptor, has also been demonstrated to synergistically augment EGF signaling in T47D breast cancer cells (27) . In NSCLC, how EGFR and JAK1 interact to exert biological effects should be further elucidated.
The present study indicated that JAK1 activation is associated with a poor prognosis in NSCLC, particularly in lung ADCC. p-JAK1 is an independent poor prognostic factor and a potential target for early diagnosis. The combination of EGFR gene amplification and JAK1 activation may be a novel tool for prognosis prediction in patients with lung ADCC.
